Bioasis Technologies Inc. Announces Stock Option Grants

NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB³ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced that it has granted stock options to acquire a total of 2,011,000 common shares effective August 8, 2022 at a price of $0.13 per share to directors and officers of the Company and an investor relations consultant. All of the options expire five years from the date of the grant and are governed by the terms of the company’s stock option plan. The options are being issued as part of annual remuneration.